“The gene therapy market is projected to grow at a CAGR of 32% in the first half of the forecast period” says new Visiongain report

06 March 2020
Pharma

Visiongain has launched a new pharma report Gene Therapy R&D and Revenue Forecasts 2020-2030: Retroviruses, Lentiviruses, Adenoviruses, Adeno Associated Virus, Herpes Simplex Virus, Poxvirus, Vaccinia Virus, Naked/Plasmid Vectors, Gene Gun, Electroporation, Lipofection, Cancer, Rare Diseases, Cardiovascular Disorders, Ophthalmologic Conditions, Infectious Disease, Neurological Disorders, Diabetes Mellitus.

The gene therapy market is in early stages of its development, this new Visiongain report analyses the emerging gene therapy market, a field holding great technological and commercial potential. Gene therapy is no longer a treatment solely for rare diseases but has expanded its targets and can now be applied to cancer, cardiovascular diseases, diabetes and more. We have already seen gene therapies launched in recent years and are likely to see upcoming launches due to rapid advancement and the number of clinical trials in this field. Gene therapy has seen many advances in recent years, particularly with vector technology, with AAV and lentiviral vectors showing much potential.

The lead analyst of the report commented "The growth of the overall gene therapy market will be primarily driven by growth in the cardiovascular and rare diseases sector. Clinical trials so far have demonstrated favourable results in a broad range of indications with treatments predicted to launch in the next few years for the cardiovascular disease, rare disease, and cancer submarkets. The market still faces substantial challenges related to ethics, pricing and scalability. Companies looking to market their products optimally should also be developing companion diagnostics for predictive biomarker testing, to market alongside their gene therapies. These companies will also need to agree on creating reimbursements models that will convince health care providers to invest in these novel therapies."

Leading companies featured in the report include UniQure, Biogen, Bluebird Bio, Spark Therapeutics, Applied Genetics Technologies Corporation, Oxford Biomedica, GenSight Biologics and other leading companies currently developing gene therapies. Leading Big Pharma Companies mentioned in this report include Pfizer, Novartis & GSK.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Healthcare Cold Chain Logistics Market Report 2020-2030

. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.

16 September 2020

Read

Visiongain Publishes Vaccines Sales Market Report 2020-2030

Visiongain forecasts a continuing growth in global market, submarket and product sales as human vaccines drive pharmaceutical business sales. New key players and technological progress will enter the industry, leading to an increase in the market size of the world market for human vaccines in general.

14 September 2020

Read

Visiongain Publishes Ophthalmic Ultrasound Systems Market Report 2020-2030

The global ophthalmic ultrasound systems market is driven by factors such as the increasing prevalence of ocular disorders and diseases, adoption of novel ophthalmic technologies, rising focus on research & development, and growing health awareness amongst the population.

09 September 2020

Read

Visiongain Publishes Drug Discovery Outsourcing Market Report 2020-2030

The current COVID-19 pandemic is anticipated to have a minor impact on the overall outsourcing business outlook for global drug discovery. Also, significant growth during the COVID-19 pandemic is expected to be seen in the outsourcing of drugs and medicines needed to treat COVID-19 infections.

07 September 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever